Pamidronate Disodium

Bisphosphonate Bone resorption inhibitor

Dosage & Administration Guidelines

Species Route Dose Frequency Duration & Clinical Notes
Dog IV 1-2 mg/kg (slow IV infusion over 2-4 hours) Single dose; may repeat in 2-4 weeks if needed Duration: As needed for hypercalcemia or bone pain
Notes: Dilute in 0.9% saline or 5% dextrose. Monitor renal function and serum calcium. For hypercalcemia, use lower end of dose.
Cat IV 1-1.5 mg/kg (slow IV infusion over 2-4 hours) Single dose; may repeat in 2-4 weeks if needed Duration: As needed for hypercalcemia or bone pain
Notes: Use with caution in cats with renal disease. Monitor serum calcium and renal parameters.
Horse IV 0.5-1 mg/kg (slow IV infusion over 2-4 hours) Single dose; may repeat in 2-4 weeks if needed Duration: As needed for hypercalcemia or bone pain
Notes: Limited data; use with caution. Monitor renal function.
Rabbit IV 1-2 mg/kg (slow IV infusion over 2-4 hours) Single dose; may repeat in 2-4 weeks if needed Duration: As needed for hypercalcemia
Notes: Off-label use; monitor renal function and serum calcium.
Reptiles IV 0.5-1 mg/kg (slow IV infusion over 2-4 hours) Single dose; may repeat in 2-4 weeks if needed Duration: As needed for hypercalcemia or metabolic bone disease
Notes: Off-label use; limited data. Use with caution.

Clinical Indications & Species Uses

General Indications
  • Hypercalcemia (malignancy-associated, primary hyperparathyroidism, granulomatous disease)
  • Osteolytic bone lesions
  • Osteoporosis (adjunctive therapy)
Dog (Canine)
  • Hypercalcemia of malignancy
  • Idiopathic hypercalcemia
  • Osteolytic bone lesions (e.g., multiple myeloma, metastatic bone tumors)
  • Canine osteoporosis (rarely used)
Cat (Feline)
  • Hypercalcemia of malignancy
  • Idiopathic hypercalcemia
  • Osteolytic bone lesions (e.g., squamous cell carcinoma, multiple myeloma)
Horse (Equine)
  • Hypercalcemia of malignancy
  • Osteolytic bone lesions (e.g., bone cysts, osteoarthritis-related bone remodeling)
Rabbit & Small Mammals
  • Hypercalcemia (rarely used)
  • Dental disease-associated osteolysis (off-label)
Exotic & Other Species
  • Hypercalcemia in reptiles (off-label)
  • Metabolic bone disease in reptiles (off-label)

Pharmacology & Mechanism of Action

Drug Class: Bisphosphonate | Pharmacological Group: Bone resorption inhibitor

Mechanism of Action: Pamidronate disodium is a second-generation bisphosphonate that inhibits bone resorption by binding to hydroxyapatite crystals in bone and inhibiting osteoclast activity. It reduces osteoclast recruitment and induces osteoclast apoptosis, thereby decreasing bone turnover and lowering serum calcium levels. It also inhibits the formation of calcium phosphate crystals and may have anti-inflammatory effects.

Pharmacodynamics: Pamidronate reduces bone turnover markers (e.g., NTx, deoxypyridinoline) and serum calcium. It increases bone mineral density and reduces pain associated with osteolytic lesions. Its effects on calcium homeostasis are dose-dependent and can last for weeks to months after a single dose.

⚡ Pharmacokinetics Summary

Absorption: Pamidronate is poorly absorbed orally (bioavailability <1% in humans); in veterinary medicine, it is administered parenterally (IV) to ensure adequate absorption. Oral absorption is further reduced by food, especially calcium-containing meals.
Distribution: Pamidronate rapidly distributes to bone, where it binds to hydroxyapatite. It has a large volume of distribution and accumulates in bone tissue. It does not cross the blood-brain barrier significantly. Protein binding is approximately 54% in humans.
Metabolism: Pamidronate is not metabolized to any significant extent. It is excreted unchanged by the kidneys.
Excretion: Pamidronate is excreted primarily by the kidneys via glomerular filtration and tubular secretion. In humans, approximately 50% of an IV dose is excreted in urine within 72 hours; the remainder is retained in bone and released slowly over months to years.
Half-Life: The terminal half-life in humans is approximately 28 hours for the distribution phase, but the bone-bound fraction has a half-life of several months to years. In dogs, the half-life is approximately 2-3 hours for the initial phase, but the terminal half-life is prolonged due to bone binding.
Bioavailability: Oral bioavailability is <1% in humans; in veterinary medicine, it is administered IV for clinical use.
Protein Binding: Approximately 54% bound to plasma proteins in humans.

Available Formulations & Strengths

Injectable Solution 3 mg/mL, 6 mg/mL, 9 mg/mL (as disodium salt) (IV)
Powder for Injection 30 mg, 60 mg, 90 mg vials (IV)

Contraindications & Clinical Warnings

Contraindications:
  • Hypocalcemia
  • Severe renal impairment (creatinine > 2.5 mg/dL or acute renal failure)
  • Known hypersensitivity to bisphosphonates
  • Pregnancy (unless benefits outweigh risks)
  • Concurrent use with other nephrotoxic drugs (relative contraindication)
Warnings & Clinical Precautions:
  • Administer only by slow IV infusion to avoid renal toxicity and local irritation.
  • Monitor serum calcium, phosphorus, and renal function before and during therapy.
  • Use with caution in patients with pre-existing renal disease, as pamidronate can cause nephrotoxicity.
  • Adequate hydration is essential to minimize renal risk.
  • May cause transient flu-like symptoms (fever, myalgia) after infusion.
  • Do not mix with calcium-containing solutions.
  • Use with caution in young animals due to potential effects on bone development.
  • In horses, use with caution in pregnant mares.

Adverse Effects & Reactions

Common:

  • Transient fever
  • Myalgia
  • Flu-like symptoms
  • Injection site reactions (if extravasation)
  • Hypocalcemia
  • Hypophosphatemia

Serious / Severe:

  • Nephrotoxicity (acute renal failure)
  • Osteonecrosis of the jaw (rare, reported in humans; potential in animals)
  • Severe hypocalcemia (with tetany or seizures)
  • Anaphylaxis (rare)

Rare:

  • Esophagitis (with oral use, not applicable in veterinary IV use)
  • Uveitis (reported in humans)
  • Atrial fibrillation (reported in humans)
  • Ocular inflammation (rare)

Key Drug Interactions

Interacting Drug / Class Clinical Effect & Mechanism Severity
Aminoglycosides Increased risk of nephrotoxicity High
NSAIDs Increased risk of renal toxicity Moderate
Loop diuretics (e.g., furosemide) Increased risk of hypocalcemia and electrolyte imbalances Moderate
Calcium-containing IV solutions Physical incompatibility; may cause precipitation High
Other nephrotoxic drugs (e.g., cisplatin, amphotericin B) Additive nephrotoxicity High

Overdose & Toxicity Management

Signs of Toxicity:

  • Severe hypocalcemia (muscle twitching, tetany, seizures)
  • Acute renal failure (oliguria, azotemia)
  • Hypophosphatemia
  • Hypomagnesemia
  • Cardiac arrhythmias (due to electrolyte disturbances)

Emergency Treatment Protocol: There is no specific antidote. Treatment is symptomatic and supportive: discontinue infusion, monitor vital signs, administer IV calcium gluconate for symptomatic hypocalcemia (if severe), correct electrolyte imbalances, ensure adequate hydration, and provide renal support (e.g., diuresis, hemodialysis if available). Monitor renal function closely.

Food Animal Withdrawal Times

Not approved for use in food animals. If used off-label in food animals, a prolonged withdrawal period should be considered; consult FARAD (Food Animal Residue Avoidance Databank) for specific recommendations.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature 20-25°C (68-77°F); protect from freezing.

Light Sensitivity: Light-sensitive — protect from direct exposure.

Handling & Special Conditions: Protect from light. After reconstitution, use immediately or store in refrigerator for up to 24 hours. Discard unused portions.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not FDA-approved for veterinary use; approved for human use (Aredia) and used extra-label in animals.

Extra-Label (Off-Label) Use: In the US, pamidronate is not FDA-approved for veterinary use; it is used extra-label under AMDUCA (Animal Medicinal Drug Use Clarification Act) in animals. For food animals, extra-label use is prohibited unless a valid VCPR and withdrawal times are established.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Pamidronate disodium is a potent bisphosphonate used in veterinary medicine primarily for the management of hypercalcemia, especially hypercalcemia of malignancy, and for osteolytic bone lesions. It is administered intravenously as a slow infusion to minimize renal toxicity. Clinical response is typically seen within 24-48 hours, with maximal effect in 3-7 days. It is important to monitor serum calcium, phosphorus, and renal function before and after administration. In dogs and cats, it is often used as an adjunct to treat the underlying cause (e.g., chemotherapy for neoplasia). In horses, it has been used for bone-related pain and hypercalcemia, but data are limited. Use in exotic species is anecdotal. Due to the risk of nephrotoxicity, adequate hydration is essential. The drug should be used with caution in patients with renal impairment, and dose adjustments may be necessary. Long-term use may be associated with osteonecrosis of the jaw, although this is rare in animals. Overall, pamidronate is a valuable tool in managing calcium and bone disorders when used appropriately.

References & Literature

  • 📚 Plumb's Veterinary Drug Handbook
  • 📚 Papich Veterinary Pharmacology and Therapeutics
  • 📚 Compendium of Veterinary Products (CVP)